Past and Current Advances in Marburg Virus Disease: a Review

Total Page:16

File Type:pdf, Size:1020Kb

Past and Current Advances in Marburg Virus Disease: a Review Le Infezioni in Medicina, n. 3 , 332-345, 2020 332 REVIEWS Past and current advances in Marburg virus disease: a review Ameema Asad1, Alifiya Aamir1, Nazuk Eraj Qureshi1, Simran Bhimani1, Nadia Nazir Jatoi1, Simran Batra1, Rohan Kumar Ochani1, Muhammad Khalid Abbasi2, Muhammad Ali Tariq3, Mufaddal Najmuddin Diwan1 1Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan; 2Department of Internal Medicine, Ziauddin Medical University, Karachi, Pakistan; 3Department of Internal Medicine, Dow International Medical College, DUHS, Karachi, Pakistan SUMMARY Marburg Virus (MARV), along with the Ebola virus, populated by the bats, are at an increased risk of con- belongs to the family of Filovirus and is cause of a lethal tracting the illness. The incubation period ranges from and severely affecting hemorrhagic fever. The Mar- 2-21 days and the clinical outcome can be broken down burgvirus genus includes two viruses: MARV and into three phases: initial generalized phase (day 1-4), Ravn. MARV has been recognized as one of utmost im- early organ phase (day 5 to 13) and either a late organ/ portance by the World Health Organization (WHO). convalescence phase (day 13 onwards). The case fatality rate of the virus ranges from 24.0 to Furthermore, the treatment of MARD is solely based 88.0% which demonstrates its lethal nature and the on supportive care. Much has been investigated in need for its widespread information. over the past half-century of the initial infection but The first case of the Marburgvirus disease (MARD) only a few treatment options show promising results. was reported in 1967 when lab personnel working In addition, special precaution is advised whilst han- with African green monkeys got infected in Germany dling the patient or the biospecimens. Disease-modify- and Serbia simultaneously. Following the initial case, ing agents and inhibitors of viral replications show many more outbreaks occurred around the world such constructive outcomes. as Uganda, Angola, Congo, Kenya and even in the It is crucial to identify the host of the virus and educate United States in 2008. It was soon found out that the the populations that are greatly at risk of the disease. MARV was a zoonotic virus and mainly contracted While much is being investigated to devise a vaccine, it from animal-to-human contact and further transmitted is important to educate Health Care Workers (HCWs) via human-to-human contact. The Egyptian fruit bat and close contacts facing the illness. Stopping the trans- (Rousettus aegyptiacus) is known to be one of the signif- mission remains the best measure that can be taken. icant sources of the infection and tourists visiting caves inhabited by these bats or workers accessing mines, Keywords: Marburg virus, Ebola virus n INTRODUCTION cludes a single species, Marburg marburgvirus, which is represented by two distinct viruses, arburg virus (MARV) is one of two viruses MARV and Ravn virus (RAVV) [1]. Both the Mof the Filovirus family in the order of Mon- EBOV and MARV genomes are about 19,000 nu- onegavirales which, along with Ebola virus cleotides long and are transcribed into eight ma- (EBOV), can cause a severe and fatal Marburg jor sub-genomic messenger RNAs (mRNAs), en- disease (MARD). The genus Marburgvirus in- coding for seven structural proteins [2]. Both vi- ruses are classified as category A pathogens by the Centers for Disease Control and Prevention Corresponding author (CDC) and select agents, with Marburg being Simran Batra rated as a Risk Group 4 Pathogen (requiring bi- E-mail: [email protected] osafety level 4-equivalent containment) by the Past, current and advances in Marburg virus disease 333 World Health Organization (WHO) [3]. The Hence, rare diseases with the possibility of fre- morphological traits of MARV when studied un- quent outbreaks must be addressed, so more clin- der a transmission electron microscope showed ical trials must be conducted to make a treatment pleomorphism, with filamentous, rod-shaped, regimen for such life-threatening diseases. There- cobra-like, spherical, and branch-shaped parti- fore, we wrote this comprehensive review of viral cles of uniform diameter but different lengths pathogenesis, clinical manifestation, manage- [4]. MARV was first discovered in 1967, when ment, and the advances made in efforts to combat outbreaks of hemorrhagic fever occurred simul- such a disease. taneously in laboratories in Marburg and Frank- furt in Germany, and Belgrade in Yugoslavia n METHODS (now Serbia). A total of 31 people became ill, in- cluding 25 laboratory workers, and medical per- A literature search was conducted using PubMed sonnel and a family member who had cared for and Google Scholar from their inception to No- them [5]. vember 2019 for this review. In order to refine the MARV is a zoonotic (animal-borne) virus and its search, the following keywords were incorporated: reservoir is the Egyptian fruit bat (Rousettus ae- (Marburg virus) AND (“epidemiology” OR “virol- gyptiacus) [6]. Previous literature shows that ma- ogy” OR “pathogenesis” OR “vector” OR “trans- jority of the primary infections of natural MARV mission” OR “reservoir” OR “symptom” OR “di- disease outbreaks so far have been linked to hu- agnosis” OR “management” OR “treatment” OR man entry into caves inhabited by bats (e.g., cave “vaccination” OR “prevention”). Any articles that visitors, mine workers) [7]. After an initial zo- were found in languages other than English were onotic transmission from an infected animal to a excluded. human occurs, the transmission is then ampli- The initial search included 2245 articles. 578 du- fied through close human-to-human contact. plicates found between Google Scholar and Pu- This can be through direct contact with bodily bMed were excluded. A total of 1667 titles and fluids and through contact with contaminated abstracts were scanned, of which 156 studies were fomites (objects or materials that are likely to found relevant. A further 14 exclusions were carry infection) [8]. made as full texts were not available for these. 142 Its clinical manifestations include abrupt onset of full texts were then retrieved, and a further 84 ex- high fever, severe headache and severe malaise clusions were made as the studies were beyond followed by severe watery diarrhea, abdominal the scope of this review. A total of 58 studies were pain with cramping, nausea and vomiting. Many included in this final review. patients develop severe hemorrhagic manifesta- tions later as the disease progresses. Both the Filo- Epidemiology viridae are associated with high case fatality rates The first outbreak of the MARD was reported in (CFR). WHO reports that the CFR of EBV ranges 1967 when the laboratory personnel working with from 25.0 to 90.0% while that of MARV ranges grivets (chlorocebusaethiops) which are green Afri- from 24 to 88% [9]. As of March 2018, there have can monkeys, brought in from Uganda, got infect- been thirteen outbreaks of MARV disease, most ed in Germany and Serbia (former Yugoslavia). occurring in sub-Saharan Africa; the largest of The grivets were reported to have been infected which occurred in Angola during 2004-2005 and with MARV and the personnel mainly contracted had a case-fatality rate of 90% [10, 11]. In lieu of the disease due to the direct handling of the tissue MARV posing a potential and severe threat to and organs of these infected wild animals [12, 13]. public health and safety, systemic surveillance is A total of 31 patients [25 primary, six secondary required to overcome its recurrence and rising infections] developed a severe illness which then mortality rates. resulted in seven of the patients dying of the dis- Considering the regular epidemics and a very re- ease [14]. Following the initial outbreak, more cas- cent pandemic, it is important to highlight the es emerged. Some of these cases supported noso- burden even of the rare diseases, primarily dis- comial transmission whilst only one case was re- eases such as MARD, which do not have a defini- ported that showed seminal transmission. A tive treatment with a high case-fatality rate. woman was reportedly infected from her hus- 334 A. Asad, A. Aamir, N.E. Qureshi, et al. band’s semen, who was already infected for al- sporadic cases supported the theory that there most three months [12]. were repeated infections. This was further con- In 1975, in Zimbabwe/South Africa three new firmed when 9 genetically different virus strains cases were reported. Amongst them was the in- were found out to be the source of transmissions dex patient who was on a visit to the Senoia caves of the disease during the outbreak. Furthermore, in Rhodesia (now Zimbabwe) with other tourists it became apparent that there had been cases in slept in places where insectivorous bats resided association with the mine in 1987 that were unre- [13, 15]. Their itinerary was a leading evidence for ported. These cases were previously called as bridging direct contact of bats and their discharge ‘hemorrhagic syndrome’ of Durba [7, 21]. Accord- as the cause of contraction of the disease [12]. ing to Languon S. et al., gold mine workers had In 1980, another outbreak was reported in Kenya. exposure to the fauna littered near the mine. The The infected patient was known to have visited mine had variety of animals such as rodents, bats, many small forested areas on multiple occasions frogs, shrews, cockroaches, and mouth flies; how- and fed the forests’ mammals and birds. Prior to ever, there was no report of direct exposure or in- the development of the illness, the patient had sect bites in the mine to the infected individuals also visited the Kitum cave with a huge popula- [12, 21]. Moreover, the work environment of the tion of bats live at Mount Elgon National park.
Recommended publications
  • A Multicenter, Multi-Outbreak, Randomized, Controlled Safety And
    2018 Ebola MCM RCT Protocol Page 1 of 92 IND#: 125530 CONFIDENTIAL 4 October 2019, version 7.0 A Multicenter, Multi-Outbreak, Randomized, Controlled Safety and Efficacy Study of Investigational Therapeutics for the Treatment of Patients with Ebola Virus Disease Short Title: 2018 Ebola MCM RCT Protocol Sponsored by: Office of Clinical Research Policy and Regulatory Operations (OCRPRO) National Institute of Allergy and Infectious Diseases 5601 Fishers Lane Bethesda, MD 20892 NIH Protocol Number: 19-I-0003 Protocol IND #: 125530 ClinicalTrials.gov Number: NCT03719586 Date: 4 October 2019 Version: 7.0 CONFIDENTIAL This document is confidential. No part of it may be transmitted, reproduced, published, or used by other persons without prior written authorization from the study sponsor and principal investigator. 2018 Ebola MCM RCT Protocol Page 2 of 92 IND#: 125530 CONFIDENTIAL 4 October 2019, version 7.0 KEY ROLES DRC Principal Investigator: Jean-Jacques Muyembe-Tamfum, MD, PhD Director-General, DRC National Institute for Biomedical Research Professor of Microbiology, Kinshasa University Medical School Kinshasa Gombe Democratic Republic of the Congo Phone: +243 898949289 Email: [email protected] Other International Investigators: see Appendix E Statistical Lead: Lori Dodd, PhD Biostatistics Research Branch, DCR, NIAID 5601 Fishers Lane, Room 4C31 Rockville, MD 20852 Phone: 240-669-5247 Email: [email protected] U.S. Principal Investigator: Richard T. Davey, Jr., MD Clinical Research Section, LIR, NIAID, NIH Building 10, Room 4-1479, Bethesda,
    [Show full text]
  • 30 SWARA October – December 2007 Maps of Kitum Cave
    1 Maps of Kitum Cave (1), Mackingeny Cave (2), sections of Kitum Cave (3), and sections of Mackingeny Cave (4). 30 SWARA October – December 2007 2 behaviour 3 Mount Elgon’s ‘elephant caves’ Joyce Lundberg and Donald McFarlane contemplate and map the extraordinary underground attractions of western Kenya’s Mount Elgon National Park. 4 SWARA October – December 2007 31 ne of Kenya’s least vis- that are far too busy eating the herbivore ited parks, the Mount equivalent of chocolate mousse to take Elgon National Park much notice of their potential fate. Oprotects a narrow band The salts are mainly mirabalite, of forest climbing the eastern flank sodium sulphate (commonly called of East Africa’s fifth highest mas- Glauber’s salt), which grows out sif, standing 4,321 metres (14,178 from the walls and can form curved crys- feet) above sea level (see map below). tals resembling pig’s tusks. The crystals are For most visitors, the Park’s principal licked off the wall by buffalos or scraped/ attraction rests in its suite of unique caves, gouged out by bushbuck and elephants. of which the Kitum and the Makingeny Buffalos cannot scrape the rock themselves, Caves are best known. Used by the Elgony so they eat mainly the leftover bits dropped people for centuries, the Elgon caves came by the elephants. The marks left by bush- to wider attention through the writings of buck teeth and elephant tusks are clearly Joseph Thomson (Through Masai Land, identifiable on the cave walls. 1885), and are thought to have been the These marks should not be confused inspiration too for H.
    [Show full text]
  • Rabbit Anti-Marburgvirus (MARV) VLP Pab ELISA Data
    4 Research Court, Suite 300 Rockville, MD 20850 877-411-2041 [email protected] Rabbit anti-Marburgvirus (MARV) VLP pAb ELISA Data: Catalog #: 04-0005 IgG IgG + IgG + Lot #: MMIG201001IBT Dilution MMARV ZEBOV 1:X Antigen Antigen Immunogen: MARV (Musoke strain) Virus-like Particles (VLPs) containing glycoprotein (GP) 1000 3.30 2.66 Nucleoprotein (NP), and viral protein (VP40). 3162 3.07 1.80 10000 2.68 0.89 Description: Protein A purified rabbit polyclonal 31623 1.87 0.37 antibody reactive to MARV VLP raised in New 100000 0.99 0.14 Zealand white rabbits. 316228 0.43 0.05 1000000 0.17 0.02 Supplied: 0.5 mg of antibody is supplied in PBS at a concentration of 5.75 mg/mL. 0.01% Sodium azide has been added. -Antigen is coated on ELISA plates overnight. -Add 200µl blocking buffer then wash wells with Clonality: Polyclonal PBST. -Antiserum is diluted semi-log. Relevance: the filovirus Marburgvirus is a -Incubate antibody for 2 hour. Category A (NIAID) and HHS select agent. -Wash unbound antibodies and add HRP- Recommended Dilutions: conjugated anti-rabbit IgG. -Wash plates and add substrate to develop color for ELISA: Assay-dependent dilution. 20 minutes. WB: Assay-dependent dilution -Read absorbance at 650nm. Amount of color is directly proportional to amount of antibodies. Storage: 2-3 weeks +4oC, -20◦C long term Western Blot Cross Reactivity: Historical data showed some cross-reactivity with Ebola Virus (EBOV) and -Antiserum recognizes Marburg musoke Sudan Virus (SUDV) VLP’s, most likely due to glycoprotein, nucleoprotein, and VP40 antibodies against Baculovirus proteins since the VLP’s were expressed in SF9-Baculovirus system.
    [Show full text]
  • Investigating the Role of Bats in Emerging Zoonoses
    12 ISSN 1810-1119 FAO ANIMAL PRODUCTION AND HEALTH manual INVESTIGATING THE ROLE OF BATS IN EMERGING ZOONOSES Balancing ecology, conservation and public health interest Cover photographs: Left: © Jon Epstein. EcoHealth Alliance Center: © Jon Epstein. EcoHealth Alliance Right: © Samuel Castro. Bureau of Animal Industry Philippines 12 FAO ANIMAL PRODUCTION AND HEALTH manual INVESTIGATING THE ROLE OF BATS IN EMERGING ZOONOSES Balancing ecology, conservation and public health interest Edited by Scott H. Newman, Hume Field, Jon Epstein and Carol de Jong FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS Rome, 2011 Recommended Citation Food and Agriculture Organisation of the United Nations. 2011. Investigating the role of bats in emerging zoonoses: Balancing ecology, conservation and public health interests. Edited by S.H. Newman, H.E. Field, C.E. de Jong and J.H. Epstein. FAO Animal Production and Health Manual No. 12. Rome. The designations employed and the presentation of material in this information product do not imply the expression of any opinion whatsoever on the part of the Food and Agriculture Organization of the United Nations (FAO) concerning the legal or development status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The mention of specific companies or products of manufacturers, whether or not these have been patented, does not imply that these have been endorsed or recommended by FAO in preference to others of a similar nature that are not mentioned. The views expressed in this information product are those of the author(s) and do not necessarily reflect the views of FAO.
    [Show full text]
  • Taï Forest Virus Does Not Cause Lethal Disease in Ferrets
    microorganisms Article Taï Forest Virus Does Not Cause Lethal Disease in Ferrets Zachary Schiffman 1,2,† , Feihu Yan 3,†, Shihua He 2, Kevin Tierney 2, Wenjun Zhu 2 , Karla Emeterio 1,2, Huajun Zhang 1, Logan Banadyga 2,* and Xiangguo Qiu 2 1 Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB R3E 0J9, Canada; [email protected] (Z.S.); [email protected] (K.E.); [email protected] (H.Z.) 2 Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada; [email protected] (S.H.); [email protected] (K.T.); [email protected] (W.Z.); [email protected] (X.Q.) 3 Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China; [email protected] * Correspondence: [email protected] † These authors contributed equally. Abstract: Filoviruses are zoonotic, negative-sense RNA viruses, most of which are capable of causing severe disease in humans and nonhuman primates, often with high case fatality rates. Among these viruses, those belonging to the Ebolavirus genus—particularly Ebola virus, Sudan virus, and Bundibugyo virus—represent some of the most pathogenic to humans. Taï Forest virus (TAFV) is thought to be among the least pathogenic ebolaviruses; however, only a single non-fatal case has been documented in humans, in 1994. With the recent success of the ferret as a lethal model for a number of ebolaviruses, we set out to evaluate its suitability as a model for TAFV. Our results demonstrate that, unlike other ebolaviruses, TAFV infection in ferrets does not result in lethal disease.
    [Show full text]
  • Risk Assessment and Risk Mitigation Review(S)
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 761169Orig1s000 RISK ASSESSMENT and RISK MITIGATION REVIEW(S) Division of Risk Management (DRM) Office of Medication Error Prevention and Risk Management (OMEPRM) Office of Surveillance and Epidemiology (OSE) Center for Drug Evaluation and Research (CDER) Application Type BLA Application Number 761169 PDUFA Goal Date October 25, 2020 OSE RCM # 2020-264 Reviewer Name(s) Elizabeth Everhart, MSN, RN, ACNP Team Leader Naomi Boston, PharmD Acting Deputy Division Doris Auth, PharmD Director Review Completion Date August 10, 2020; date entered into DARRTS, August 20, 2020 Subject Evaluation of Need for a REMS Established Name atoltivimab – odesivimab – maftivimab (REGN-EB3) Trade Name Inmazeb Name of Applicant Regeneron Pharmaceuticals, Inc. Therapeutic Class Human IgG monoclonal antibody Formulation Solution for infusion Dosing Regimen 50 mg of each mAb/kg (3mL/kg) IV (b) (4) × 1 1 Reference ID: 4659652 Table of Contents EXECUTIVE SUMMARY ............................................................................................................................................................3 1 Introduction........................................................................................................................................................................3 2 Background .........................................................................................................................................................................3 2.1 Product Information..............................................................................................................................................3
    [Show full text]
  • 761169Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 761169Orig1s000 OTHER REVIEW(S) LABEL AND LABELING REVIEW Division of Medication Error Prevention and Analysis (DMEPA) Office of Medication Error Prevention and Risk Management (OMEPRM) Office of Surveillance and Epidemiology (OSE) Center for Drug Evaluation and Research (CDER) *** This document contains proprietary information that cannot be released to the public*** Date of This Review: October 7, 2020 Requesting Office or Division: Division of Antivirals (DAV) Application Type and Number: BLA 761169 Product Name, Dosage Form, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) and Strength: Injection 241.7 mg/241.7 mg/241.7 mg per 14.5 mL (16.67 mg/16.67 mg/16.67 mg per mL) Product Type: Multi-Ingredient Product Rx or OTC: Prescription (Rx) Applicant/Sponsor Name: Regeneron Pharmaceuticals, Inc. (Regeneron) FDA Received Date: February 25, 2020 OSE RCM #: 2020-263 DMEPA Safety Evaluator: Valerie S. Vaughan, PharmD DMEPA Associate Director of Mishale Mistry, PharmD, MPH Nomenclature and Labeling: 1 1 REASON FOR REVIEW As part of the approval process for Inmazeb injection, 241.7 mg/241.7 mg/241.7 mg per 14.5 mL (16.67 mg/16.67 mg/16.67 mg per mL), the Division of Antivirals (DAV) requested that we review the proposed labels and labeling for areas that may lead to medication errors. 2 MATERIALS REVIEWED We considered the materials listed in Table 1 for this review. The Appendices provide the methods and results for each material reviewed. Table 1. Materials Considered for this
    [Show full text]
  • Ebola Virus Disease (EVD), Implications of Introduction in the Americas
    Ebola virus disease (EVD), implications of introduction in the Americas Corrigendum1 - 13 August 2014 Given the current situation of Ebola virus disease (EVD) in West Africa, the Pan American Health Organization / World Health Organization (PAHO/WHO) advises its Member States to remain vigilant for potential introduction of EVD in the Americas, to raise the awareness and knowledge of health care providers and to strengthen the implementation of standard precautions for infection prevention and control in health care facilities at all levels. 1. Ebola virus disease (EVD) – Key facts Ebola virus disease (EVD), formerly known as Ebola haemorrhagic fever), is a severe, often fatal illness, with a case fatality rate of up to 90%. There are no licensed specific treatments or vaccine available for use in people or animals. Genus Ebolavirus is 1 of 3 members of the Filoviridae family (filovirus), along with genus Marburgvirus and genus Cuevavirus. Genus Ebolavirus comprises 5 distinct species: Bundibugyo ebolavirus (BDBV), Zaire ebolavirus (EBOV), Reston ebolavirus (RESTV), Sudan ebolavirus (SUDV) and Taï Forest ebolavirus (TAFV). The incubation period of Ebola virus disease (EVD) varies from 2 to 21 days, with an observed average of 8 to 10 days. Following the introduction of Ebola virus in the human population through animal-to-human transmission, person-to-person transmission by direct contact body fluids/secretions of infected persons is considered the principal mode of transmission. Indirect contact with environment and fomites soiled with contaminated bodily fluids (e.g. needles) may also occur. Airborne transmission has not been documented during previous EVD outbreaks. There is no risk of transmission during the incubation period.
    [Show full text]
  • Ebola and Marburg Virus Disease Epidemics: Preparedness, Alert, Control and Evaluation
    EBOLA STRATEGY Ebola and Marburg virus disease epidemics: preparedness, alert, control and evaluation August 2014 © World Health Organization 2014. All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. WHO/HSE/PED/CED/2014.05 Contents Acknowledgements ............................................................................................................ 5 List of abbreviations and acronyms ................................................................................... 6 Chapter 1 – Introduction .................................................................................................... 7 1.1 Purpose of the document and target audience ....................................................................
    [Show full text]
  • Filovirus (FV)
    Summary Filovirus is transmitted to Summaryhumans or monkeys through wild animals and by direct contact Lorem ipsum dolor sit amet, of infected bodily fluids from consectetur adipiscing elit, sed human to human. Hemorrhagic do eiusmod tempor incididunt ut fever, organ failure and internal/ labore et dolore magna aliqua. external bleeding are the clinical Ut enim ad minim veniam, quis signs in humans and nonhuman nostrud exercitation ullamco primates. The most common laboris nisi ut aliquip ex ea method for screening for filovirus commodo consequat. in nonhuman primate colonies is by MFIA or ELISA using serum for detection of infected antibodies. RESEARCH MODELS AND SERVICES Filovirus (FV) Classification when two outbreaks of Ebola occurred in northern Zaire Single-stranded, negative-sense RNA, enveloped and southern Sudan. Five species of Ebolavirus have been identified to date: Zaire, Sudan, Bundibugyo, Taï Forest Family (formerly Ivory Coast), and Reston, Virginia, USA. In 1989, Filoviridae filovirus was introduced into a NHP colony in Reston from Affected Species animals originating from the Philippines. Ebola-Reston is the only known filovirus that does not cause severe disease in Nonhuman primates (NHPs) (chimpanzee, monkey, humans; however, it can still be fatal in monkeys. macaque, orangutan, and baboon) and humans The virus is transmitted to people from wild animals and Frequency spreads in the human population through human-to- The risk of NHPs in commercial primate colonies becoming human transmission. The exact transmission mode from infected with filovirus is extremely low. However, filoviruses the natural virus reservoir to a host (nonhuman primate) are zoonotic and transmissible to humans from infected is unknown.
    [Show full text]
  • Abstract Booklet
    World Society for Virology | 2021| Virtual | Abstracts Platinum Sponsor Gold Sponsors Silver Sponsor The World Society for Virology (WSV) is a non-profit organization established in 20171 to connect virologists around the world with no restrictions or boundaries, and without membership fees. The WSV brings together virologists regardless of financial resources, ethnicity, nationality or geographical location to build a network of experts across low-, middle- and high-income countries.2 To facilitate global interactions, the WSV makes extensive use of digital communication platforms.3-8 The WSV’s aims include fostering scientific collaboration, offering free educational resources, advancing scientists’ recognition and careers, and providing expert virology guidance. By fostering cross-sectional collaboration between experts who study viruses of humans, animals, plants and other organisms as well as leaders in the public health and private sectors, the WSV strongly supports the One Health approach. The WSV is a steadily growing society with currently more than 1,480 members from 86 countries across all continents. Members include virologists at all career stages including leaders in their field as well as early career researchers and postgraduate students interested in virology. The WSV has established partnerships with The International Vaccine Institute, the Elsevier journal Virology (the official journal of the WSV) and an increasing number of other organizations including national virology societies in China, Colombia, Finland, India, Mexico, Morocco and Sweden. Abdel-Moneim AS, Varma A, Pujol FH, Lewis GK, Paweska JT, Romalde JL, Söderlund-Venermo M, Moore MD, Nevels MM, Vakharia VN, Joshi V, Malik YS, Shi Z, Memish ZA (2017) Launching a Global Network of Virologists: The World Society for Virology (WSV) Intervirology 60: 276–277.
    [Show full text]
  • Marburg Hemorrhagic Fever
    Marburg Hemorrhagic Fever Marburg hemorrhagic fever (Marburg HF) is a rare but severe hemorrhagic fever which affects both humans and non-human primates. Marburg HF is caused by Marburg virus, a genetically unique zoonotic (or, animal-borne) RNA virus of the filovirus family. The five species of Ebola virus are the only other known members of the filovirus family. Marburg virus was first recognized in 1967, when outbreaks of hemorrhagic fever occurred simultaneously in laboratories in Marburg and Frankfurt, Germany and in Belgrade, Yugoslavia (now Serbia). Thirty-one people became ill, initially laboratory workers followed by several medical personnel and family members who had cared for them. Seven deaths were reported. The first people infected had been exposed to imported African green monkeys or their tissues while conducting research. One additional case was diagnosed retrospectively. The reservoir host of Marburg virus is the African fruit bat, Rousettus aegyptiacus. Fruit bats infected with Marburg virus do not to show obvious signs of illness. Primates (including humans) can become infected with Marburg virus, and may develop serious disease with high mortality. Further study is needed to determine if other species may also host the virus. This Rousettus bat is a sighted, cave-dwelling bat widely distributed across Africa. Given the fruit bat's wide distribution, more areas are potentially at risk for outbreaks of Marburg HF than previously suspected. The virus is not known to be native to other continents, such as North America. Marburg HF typically appears in sporadic outbreaks throughout Africa; laboratory confirmed cases have been reported in Uganda, Zimbabwe, the Democratic Republic of the Congo, Kenya, Angola, and South Africa.
    [Show full text]